Cart
sales@molnova.com
Isoagarotetrol
CAS No. 104060-61-9
Isoagarotetrol( —— )
Catalog No. M21808 CAS No. 104060-61-9
Isoagarotetrol is a natural product isolated from agalwood.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 132 | In Stock |
|
| 10MG | 211 | In Stock |
|
| 25MG | 356 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIsoagarotetrol
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsoagarotetrol is a natural product isolated from agalwood.
-
DescriptionIsoagarotetrol is a natural product isolated from agalwood.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number104060-61-9
-
Formula Weight318.32
-
Molecular FormulaC??H??O?
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C=C(CCC1=CC=CC=C1)O2)C3=C2[C@H](O)[C@@H](O)[C@H](O)[C@H]3O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yasuo Shimada, et al. Studies on the agalwood (jinko). IV Structures of 2-(2-phenylethyl)chromone derivatives, agarotetrol and isoagarotetrol. 1986,34(7): 2766-2773.
molnova catalog
related products
-
DL-Methionine Methyl...
DL-Methionine Methylsulfonium Chloride is a natural product?used in the treatment of peptic ulcers colitis and gastritis.
-
VIP Antagonist
VIPhyb (compound VIPhyb) is a vasoactive intestinal polypeptide (VIP) receptor antagonist that can be used in the study of cancers such as non-small cell lung cancer (NSCLC).
-
Aschantin
Aschantin, a bisepoxylignan, can be isolated from Magnolia biondii. Aschantin has antiplasmodial, Ca2+-antagonistic, platelet activating factor-antagonistic, and chemopreventive activities. Aschantin is a mTOR kinase inhibitor. Aschantin is also an inhibitor of Cytochrome P450 and UGT enzyme.
